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ead toxicity is not a problem of
the past, nor is it the exclusive
domain of children. In fact, lead con-
tinues today to pose a serious threat to
the health of many U.S. adults.
It’s true that in the United States,
environmental lead levels are much
lower than before the toxic metal was
removed from gasoline, food cans, and
other products in the 1970s and early
1980s. The National Health and
Nutrition Examination Surveys have
shown that average adult blood lead
levels have declined from about
15 µg/dL in the 1970s to today’s
1–2 µg/dL. But there are still pockets
of high exposures, such as among
workers in certain industries.
Despite reductions in exposure fol-
lowing OSHA’s 1978 publication of
lead standards for general industry,
more than 80% of elevated lead levels
in adults come from workplace expo-
sures. Industries most affected include
lead mining, refining, and smelting;
construction work involving paint
removal, demolition, and mainte-
nance of outdoor metal structures
such as bridges and water towers; auto
repair; and battery manufacturing and
recycling. 
When workplaces adhere to the
OSHA standard, occupational expo-
sures are usually reduced below levels
that cause symptomatic lead poisoning.
But as far back as 1990, studies have
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suggested that significant health effects hap-
pen at levels below those allowed by OSHA.
“Historically people had huge lead expo-
sures, so the OSHA standard, when it was
originally established, was protective. But
right now nobody thinks that that’s a protec-
tive standard,” says Rosemary Sokas, director
of the Division of Environmental and
Occupational Health Sciences at the
University of Illinois at Chicago School of
Public Health.
Now scientists say the evidence is over-
whelming that action needs to be taken to
further reduce lead exposures in both the
workplace and the general environment.
“What’s driving concern over the need to
reduce permissible levels of exposure in the
workplace are . . . more subtle or chronic
problems such as hypertension, and contri-
butions to cognitive dysfunction,” says
Michael Kosnett, an associate clinical profes-
sor of clinical pharmacology and toxicology
at the University of Colorado Health
Sciences Center.
With the lower levels of lead found in
the general population in the United States,
much of the worry is about
lead’s health effects over the
long haul. The most recent
evidence from epidemiologi-
cal and toxicological studies
suggests that low levels of
exposure can, over time,
damage the heart, kidneys,
and brain. Some of these
health effects, such as a
1-mm rise in blood pressure
or a slight cognitive decline,
seem small when expressed as
the average impact to the
entire population. In one
individual, they may not
even be noticed. But the
overall impact on public
health nevertheless worries
scientists. 
Better Tools to Measure
Smaller Effects
Tests to measure lead expo-
sure itself and its health
effects have become more
sophisticated. The blood lead
level, long the gold standard
for assessing risk, reflects the
amount of lead circulating in
the body at the time of the
test but may not offer a reli-
able indication of an individ-
ual’s past or cumulative
exposure. For example, simi-
lar blood lead concentrations
in two individuals (or popu-
lations) do not necessarily
translate to similar exposure histories. One
reason is that the body stores lead in the
bone, and it’s released from the bone into
the blood at differing rates, depending on
age, gender, and other factors. For instance,
lead will mobilize from bone more quickly
in people with conditions in which the body
is resorbing bone, such as pregnancy or
osteoporosis.
Stores of lead in bone are a more reliable
marker of cumulative lead exposure. In the
late 1980s a noninvasive way of measuring
bone lead emerged, using X-ray fluorescence
technology. Scientists began applying the
technique in epidemiological studies in the
1990s. But since the technology is available
at only a handful of institutions in the
United States, it isn’t currently feasible for
routine medical management.
Measurement of lead’s health effects have
improved as well. Studies of cognitive func-
tion, for example, now have the benefit of
more sensitive markers, including tests of
memory, visuospatial function, and the abil-
ity to communicate or understand commu-
nication. In addition, studies with larger
sample sizes and those that look at commu-
nity-based populations, not just occupation-
ally exposed workers, have sharpened the
picture of the effects. “Industry studies of
workers suffer from a number of method-
ological limitations, such as the inability to
follow workers who leave the industry,” says
Howard Hu, chairman of the Department of
Environmental Health Sciences at the
University of Michigan School of Public
Health. 
Much of the evidence in humans comes
from epidemiological studies, which show
associations between lead and health effects,
although alone they don’t definitively prove
causation. But animal studies support many
of these findings and suggest mechanisms for
some of these health effects. 
Putting Pressure on the Heart
According to Stephen Rothenberg, a senior
researcher at Centro de Investigación y de
Estudios Avanzados-Mérida in Yucatán,
Mexico, the cardiovascular system is the most
thoroughly studied system in adults in terms
of lead’s effects. A large number of these stud-
ies have investigated the
effects of lead on blood pres-
sure. Increases in both blood
lead and bone lead appear to
be associated with blood
pressure increases. 
Many epidemiological
studies in humans suggest
that rising blood lead corre-
lates with rising blood
pressure. Overall, most epi-
demiological studies of the
general population have
shown a 1-mm increase in
systolic pressure for every
doubling of blood lead, and
this increase has been seen at
a range of concentrations,
from 1 to 40 µg/dL. “When
applied to large numbers of
people,” Rothenberg says,
“those increments shift the
blood pressure curve to the
right, to higher values,
meaning that anywhere from
tens or hundreds of thou-
sands more people . . . to
tens to hundreds of millions
more are going to have blood
pressures that are higher than
most physicians currently
think is safe.” 
In the last 15 years,
about a dozen studies have
also tied bone lead to blood
pressure increases. For exam-
ple, in a longitudinal study
published in the 15 January
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2001  American Journal of Epidemiology,
Yawen Cheng of Harvard Medical School
and colleagues found that in men who began
the study without hypertension, baseline
bone lead level predicted development of the
condition six years later. 
Rothenberg points out
that although blood lead
primarily reflects recent
exposures, it can also in part
reflect the leaching of bone
lead stores back into the
bloodstream. “The combi-
nation of these two results—
significant blood lead effects
on blood pressure, and sig-
nificant bone lead effects
on blood pressure—makes
researchers feel that past
exposures, especially when
current exposure is low, may
be the dominant factor in
determining lead effects on
blood pressure,” he says.
Lead is also associated with
increased mortality from dis-
eases of the heart. In a study
published 26 September 2006
in Circulation, Andy Menke of
Tulane University and col-
leagues found an increased
risk of death from all causes
as well as from cardiovascular
disease and stroke in associa-
tion with blood lead concen-
trations as low as 2 µg/dL.
The study analyzed data from
more than 13,000 partici-
pants in the Third National
Health and Nutrition Exam-
ination Survey Mortality Study.
An editorial accompany-
ing the Circulation article
points out some of its limi-
tations, including the fact
that participants’ mortality
could have resulted in part
from higher lead exposures
that occurred prior to the
study period. But the editorial also states
that the report “breaks new ground by
extending the dose–effect relation to con-
siderably lower blood lead concentrations
than reported in previous studies.”
Study coauthor Paul Muntner, an asso-
ciate professor of epidemiology at Tulane
University, says these associations stayed
“remarkably consistent” across subgroups,
including smokers, diabetics, males, and
females. The consistent results suggest the
associations aren’t likely due to chance or
other artifacts, he says. 
So, how does lead actually cause cardio-
vascular effects? Animal studies show that
lead can promote the growth of vascular
smooth cells, which play a role in the forma-
tion of atherosclerotic plaques. Lead’s pro-
motion of oxidative stress is thought to play
a role in its cardiovascular effects (as it is in
other lead-linked health effects). Oxidative
stress happens when chemically reactive oxy-
gen and nitrogen damage cells in a process
similar to how oxygen rusts metal.
Damage from lead-induced oxidative
stress has been demonstrated in studies of
rats as well as in studies of human cells in
culture, says N.D. Vaziri, chief of the
Division of Nephrology and Hypertension
at the University of California, Irvine,
Medical Center. In Vaziri’s studies of human
endothelial cells, for instance, development
of oxidative stress has been seen immediate-
ly after lead exposure.
But in animals it takes 10 to 12 weeks for
lead exposure to result in hypertension, and
in humans it likely takes years to decades,
Vaziri says. One possible reason is that the
body launches a variety of defense mecha-
nisms that prevent or minimize rapid rise in
blood pressure and gross tissue damage.
However, over time, these defense mecha-
nisms gradually fail, blood
pressure begins to rise, and
detectable tissue damage
appears.
Vaziri demonstrated this
progression in cell culture
studies published in the May
2000 issue of the American
Journal of Hypertension.
Immediately after lead expo-
sure, the levels of a free radi-
cal called superoxide rose,
“but then the cells are able to
defend themselves,” Vaziri
says. “A day later, the super-
oxide went down, but an
enzyme that is made to cap-
ture the free radicals and
temporarily prevent them
from causing damage—the
enzyme called superoxide
dismutase—went up. So we
had a reduction in superox-
ide at an interim period. But
the defending enzyme con-
verts superoxide to hydrogen
peroxide, which is less toxic
than the original free radical
but still toxic, and capable of
causing injury and dysfunc-
tion upon prolonged expo-
sure.” Thus, Vaziri explains,
the organism mounts a
defense that is able to, at least
for the time being, prevent
the expression of disease and
injury as such. Ultimately,
however, lead exhausts the
system.
Filtering the Evidence
on Kidney Function
Epidemiological studies of
the general population suggest that kidney
function may be altered at the lowest levels
of blood lead studied to date in relation to
renal effects. In a review published in the
December (2) 2006 issue of Kidney
International, E.B. Ekong and colleagues at
The Johns Hopkins University wrote that
lead contributed to kidney damage at con-
centrations below 5 µg/dL. “Many different
studies—in Europe, Asia, and the United
States—have shown that higher blood lead
levels are associated with lower creatinine
clearance, indicating worse kidney func-
tion,” says Virginia Weaver, an associate pro-
fessor of environmental health sciences at
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Renal reality. Studies show that higher blood lead concentrations are linked to
decreases in kidney function.Johns Hopkins and one of the authors of the
review.
Some of these studies have been longitu-
dinal, which helps address a chicken-and-
egg question: is kidney damage associated
with higher blood lead levels because lead
causes the damage, or because damaged kid-
neys can’t excrete lead? “If you look at the
longitudinal data, initial lead level predicts
subsequent decline in renal function,”
Weaver says.
In addition, lead’s effects on the kidneys
are thought to play a major role in its
effect on blood pressure. This is because
the kidneys help regulate blood volume
and vascular tone, which are the principal
determinants of blood pressure. “The kid-
ney is the pathway through which we get rid
of the excess salt and fluids. Consequently,
impairment of the kidney’s ability to effi-
ciently excrete salt and fluids can result in
the rise in blood volume and, hence, blood
pressure,” Vaziri says. “Also, the kidney pro-
duces hormones that regulate the tone of
blood vessels. Thus, alterations of kidney
function or structure can cause the blood
vessels to constrict throughout the body,
thereby raising blood pressure.”
Small But Measurable Cognitive
Declines
Some studies of lead workers have shown
associations between blood lead concentra-
tions of 20 to 40 µg/dL and subclinical cog-
nitive decline, in-
cluding changes  in
memory or mental
processing speed that
are measurable but
don’t put an indi-
vidual outside the
normal range of
function. “Effects of
lead at these levels
may be such that in
any one person they
wouldn’t be able to
notice a difference,”
says Kosnett. But as
with cardiovascular
effects, when aver-
aged across the
whole population,
there’s a measurable
effect.
Declines in cog-
nitive function are
more likely to be
associated with lower-
level environmental
exposures over time, rather than recent acute
exposures. “Some of the literature suggests
that lead may contribute to or accelerate an
age-related decline in cognitive  function,”
Kosnett says. “That may be a consequence of
cumulative lead exposure.” 
One subgroup especially vulnerable to
the effects of low-level lead exposure are preg-
nant women, whose exposure may affect
their offspring’s cognitive function. In the
May 2006 issue of EHP, Lourdes Schnaas of
the Mexican National Institute of Peri-
natology and colleagues published one of the
few studies of this relationship to pinpoint
prenatal lead exposure as a greater risk to off-
spring IQ than childhood exposure. Previous
studies had shown the strongest effects with
postnatal exposure. In the EHP study,
though, prenatal exposure had a more signif-
icant effect than postnatal exposure, and the
strongest effects were seen at the lowest levels
of exposure, says Rothenberg, a coauthor on
the study. The pregnant women’s blood lead
concentrations ranged from 1 to 33 µg/dL,
with a mean level of 8 µg/dL.
In other neurotoxic effects, animal stud-
ies have suggested that lead exposure increas-
es the risk of brain cancer. Some association
studies in humans also have suggested a link.
For instance, a 1 September 2006 report in
the International Journal of Cancer by Edwin
van Wijngaarden, an assistant professor of
community and preventive medicine at the
University of Rochester, showed that workers
in jobs with high lead exposure were more
likely than unexposed subjects to die from
brain cancer. The study’s value lies in its large
sample size; it analyzed the lead–brain cancer
death association among more than 300,000
subjects in the National Longitudinal
Mortality Study, a prospective census-based
study of the U.S. population. But the study
did not measure actual lead exposure;
instead, Wijngaarden used participants’ self-
reported occupations and the job exposure
matrix developed by the National Cancer
Institute (NCI) to estimate lead exposure.
“This data set and the occupational job
exposure matrix that NCI has come up with
certainly gave me a lot more statistical power
than any of the studies [regarding lead expo-
sure and brain cancer] that have been pub-
lished so far,” Wijngaarden says.
Wijngaarden is now recruiting partici-
pants for a pilot study in which he will meas-
ure bone lead in patients with brain tumors.
“The main goal is to get a system ready for a
larger study and to get preliminary data,” he
says. No studies to date have measured bone
lead in cancer patients.
Despite these findings, however, studies
of brain cancer and lead have been inconsis-
tent—some studies have found elevated rates
of brain cancer associated with lead exposure,
and some have not. For cancer in general,
most studies show a positive association
between low levels of lead exposure and can-
cer, but with relatively few cancer deaths, says
Kyle Steenland, a professor of environmental
and occupational health at Emory University.
Is There Any Safe Level of Lead? 
Current research hasn’t been able to deter-
mine a threshold for many of lead’s effects.
That is, scientists haven’t yet found a con-
centration of lead below which no effect
occurs. Some scien-
tists say that deter-
mining a threshold
would require long-
term prospective
studies of adults
with blood lead lev-
els commonly found
in the current popu-
lation. “We need to
be able to character-
ize the dose–response
curve at very low lev-
els of exposure if
these data are going
to be used to intel-
ligently plan regula-
tion,” Rothenberg
says.
Scientists dis-
agree on just how low
measurements need
to go. “Is it going to
do us much good to
reduce the standard
for intervention for
kids or pregnant women from ten to five
[µg/dL], or do we really have to get down to
one or below in order to prevent measurable
damage?” says Rothenberg. Further, policy
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Cognition and cancer. Lead exposure is known to cause declines in brain function, but the link to
brain cancers is less clear. Environmental Health Perspectives • VOLUME 115 | NUMBER 1 | January 2007 A 35
makers will want to know if
there is a level of blood lead
below which the resulting
improvement in public
health no longer outweighs
the cost of further exposure
reduction. “We won’t know
where that turnover point in
the cost–benefit function is
until we include studies that
reliably measure blood lead
in many subjects below
point-one micrograms per
deciliter,” he says.
Rothenberg suggests that
scientists should take ad-
vantage of advanced tech-
nologies such as inductively
coupled plasma–mass spec-
trometry to measure ultralow
levels of blood lead—below
1 µg/dL. That technology
isn’t widely available, and it’s
at least five times more
expensive than current meth-
ods used to measure blood
lead.
Hu agrees that to better
define risk, prospective stud-
ies are needed of adults with
low to modest lead exposure
(in the blood lead range of
1 to 10 µg/dL). But he
believes that studying levels
below 1 µg/dL would be
“overkill.” 
Weaver cautions that
though population studies
clearly show health effects at
blood lead levels below
5 µg/dL, it’s hard to rule out
the possibility that those
health effects were caused by
past higher exposures. “We don’t know if this
is a cohort effect and how much of these
health effects will further decrease as lead
exposure continues to decline,” she says. 
At least one longitudinal study supports
the idea that health effects seen at low blood
lead levels aren’t artifacts of higher past
exposures. The Normative Aging Study,
conducted among more than 2,000 men in
Boston,  showed lasting renal effects in a
group that was known to have maintained
blood lead levels below 10 µg/dL since
1979. “They found some of the strongest
associations in that group,” Weaver says.
Still, the group could have had higher expo-
sures before 1979.
“That’s always the trick with a cumulative
toxicant,” Weaver says. “The blood levels you
see today could have been much higher in the
past. You don’t have any way of telling unless
you do bone lead measurements in everyone.”
Medical Management
Physicians can get some idea of cumulative
exposure by measuring blood lead regularly.
“For any employer or employee who is fac-
ing a job in which there’s lead exposure, tak-
ing regular blood leads, keeping those
records, and periodically calculating a cumu-
lative exposure index is inexpensive and reli-
able,” Hu says.
What’s a reasonable blood lead level in
someone who’s exposed to lead on the job?
Hu says that at levels at or below 20 µg/dL,
a worker is assuming some increased risk
but an amount that may be acceptable. “If
you have a blood lead of twenty for a work-
ing lifetime—let’s say forty-five years—you
will get a cumulative blood lead index
that we calculated would be equivalent to a
bone lead of a certain level,” Hu says.
“That bone lead level in our epidemiology
studies still corresponds to a certain
excessive risk of developing
hypertension and declined
cognition. But it’s not great-
ly above what the general
population sees.”
Kosnett recommends
that at occupational expo-
sures as low as 10 µg/dL,
physicians should increase
monitoring and reduce lead
exposures. He recommends
removing people from all
lead exposure when blood
lead levels are at 20 µg/dL
and remain there when a sec-
ond measurement is taken
four weeks later, or if a single
check registers a level of
more than 30 µg/dL.
By contrast, OSHA’s cur-
rent lead standard doesn’t
require full removal from
exposure until blood lead
concentrations exceed an
average of 50 µg/dL over
three successive tests or two
back-to-back measurements
of 60 µg/dL. Scientists have
been calling for reductions in
these cutoffs as far back as
1991. But OSHA has long
been reluctant to revise stan-
dards proactively, says Sokas,
who once served as chief
medical officer at OSHA. 
“The lead standard is
very strong in terms of wage
replacement if blood lead is
above a certain cut line,”
says Kenneth Rosenman,
chief of the Division of
Occupational and Environ-
mental Medicine at Michi-
gan State University. And the standard
does include a provision that, even at
blood lead levels below the mandatory
cutoffs, physicians can recommend med-
ical removal when workers have a specific
medical condition, with these workers
entitled to the same job and salary protec-
tion as those whose blood lead levels rise
above the 50/60 µg/dL cutoff.
Still, although that provision protects
against overt lead poisoning, it does noth-
ing to promote preventative removal at
lower levels—such as 20 µg/dL—that
may pose long-term health risks. By the
same token, there’s nothing in the law
that prohibits a pregnant woman from
working with lead until her blood level
reaches 60 µg/dL. Indeed, a 1991 Supreme
Court decision in the case of Automobile
Workers v. Johnson Controls held that pre-
cluding such women from exposure
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Blood and bone. Measurements of lead in the body are taken from blood and
bone, but each has limitations. More accurate methods are needed, particularly to
measure effects of low-level exposures.would be unlawfully discriminatory. “So on
the books now, it’s still acceptable for a preg-
nant woman to be highly exposed to lead to
the same degree as men, even though the evi-
dence is overwhelming that fetuses are
exquisitely vulnerable to lead,” Hu says.
In the past, OSHA has touted its empha-
sis on voluntary medical surveillance pro-
grams and other measures to reduce exposure.
Industry tends to favor voluntary exposure
reduction as well. “The science has developed
since the last time the OSHA standard was
visited, and we’re aware of that,” says David
Weinberg, counsel for the Battery Council
International. “I’m not sure it’s necessary that
OSHA reopen the lead standard. The battery
industry and the secondary smelter industry
have worked pretty hard on these issues, and
have worked with and expect to continue to
work with OSHA and others in voluntary
programs to make sure that the progress that’s
been made continues.”
Protection for the Most Vulnerable
Other subgroups that are very susceptible to
lead exposure are emerging, and scientists
say these groups pose another reason that
regulations should be strengthened. Peo-
ple with certain genetic susceptibilities
might constitute one such group. “It’s been
recognized for a long time that there can be
considerable interindividual variability in
people’s susceptibility to the development of
symptomatic lead poisoning,” Kosnett says. 
Even at a blood lead level as high as
60 µg/dL, for instance, some people will
show symptoms and others won’t. Now, sci-
entists are finding that the same is true of the
emergence of health effects at very low levels
of lead exposure, and recent research sug-
gests that genetic variations may play a role.
“Further research is needed to explore and
understand this aspect of gene–environment
interaction,” Kosnett says.
People who already have medical condi-
tions are also at increased risk. In the
November 2006 issue of EHP, Hu and col-
leagues showed that lead exposure was asso-
ciated with increased heart rate variability
(an indicator of poor cardiovascular health),
especially in people with metabolic syn-
drome, a cluster of conditions including
obesity, high blood sugar, and high blood
pressure. People with any or all of these con-
ditions are also known to be at increased risk
for kidney damage and so may be more sus-
ceptible to lead’s effects. “With the obesity
epidemic in so many countries, diabetes and
hypertension are increasing, so we do have
more groups at risk,” Weaver says. 
Such studies point to another reason
why lead exposure is very much a problem
of the present. “As a nation, the work force
is aging, and we’re expecting ourselves and
our workers to keep working when they’re
older,” Hu says. “But that means that a lot
of them will have medical conditions, and
we have to anticipate their vulnerability to
environmental risk factors like lead.”
Muntner says that more work is needed
to find effective and safe interventions for
lowering lead exposure at the population
level for people whose blood lead concen-
trations are already below 10 µg/dL. He
points out that although blood lead levels
have decreased substantially in the last
30 years, they are still much higher than
they were in preindustrial times, before
humans began spreading lead into the air,
water, and soil. 
“So we need to not be complacent and
say, ‘We’ve lowered lead,’ but rather we need
to think about it in terms of how can we
reduce lead more, such that we eliminate
this environmental toxicant,” Muntner says.
“There’s really no biological function of
lead, and there’s really no reason why we
should be exposed to it.” 
Angela Spivey
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